# Selank: Research Overview > Selank: Research Overview — Clarity Peptide Labs — A citation-anchored research summary of selank, a tuftsin-derived anxiolytic heptapeptide studied for GABAergic modulation and BDNF signaling. Mechanism, findings, community-reported effects and safety cautions. **02 / COGNITIVE & NOOTROPIC RESEARCH** A synthetic analog of the immune peptide tuftsin, studied as a non-benzodiazepine anxiolytic acting through GABA receptors and the endogenous opioid system. ## The short version Selank is a lab-made peptide built by extending a naturally occurring immune-system peptide called tuftsin with an added tail, the same stabilizing trick used in semax, to slow its breakdown in the body. It is studied mainly as an anxiolytic — something proposed to reduce anxiety — through a route that does not involve benzodiazepine-type sedation. Its research base includes rat studies of anxiety and GABA-related gene expression, and a small set of human studies from Russian clinical practice in patients with anxiety-related disorders. It is not approved by the FDA for any indication; its only regulatory registration as an anxiolytic exists in Russia. Outside that context it is sold, where available, strictly as a research chemical. People in nootropic and peptide-user communities also report using it informally for anxiety, described further down this page — those reports are anecdotal, not clinical evidence, and this page recommends no human dose for anyone. ## What it is Selank (full sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide. Its backbone is tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally a fragment of the IgG antibody heavy chain, extended at the C-terminus with the same Pro-Gly-Pro tripeptide used in semax to improve metabolic stability and slow enzymatic degradation. Because it descends from an immune-signaling peptide rather than a hormone fragment, selank carries a documented immunomodulatory profile alongside its anxiolytic and nootropic effects — a distinctive feature among the compounds on this desk. ## How it works Selank's anxiolytic and nootropic effects in animal and limited human research are attributed to two principal, non-benzodiazepine mechanisms. First, it behaves as a **positive allosteric modulator of GABA receptors** — the brain's main inhibitory signaling system — with subtype-selective, concentration-dependent effects that differ from benzodiazepines, and it can block the modulatory activity of diazepam and olanzapine at the same receptor site, pointing to distinct but overlapping binding [8]. Second, like semax, it **inhibits enkephalin-degrading enzymes**, stabilizing the body's own endogenous opioid peptides and engaging the anti-anxiety-linked opioid system. Beyond those two routes, selank also alters serotonin and dopamine turnover, increases BDNF expression in the rat hippocampus [11], and modulates Th1/Th2 cytokine balance — an immunomodulatory profile distinct from classical anxiolytics [12]. In a rat model of unpredictable chronic mild stress, combining selank with the benzodiazepine diazepam was the most effective intervention tested for reducing anxiety, restoring behavior toward pre-stress levels and supporting a genuine GABAergic interaction rather than a coincidental overlap [9]. ## What the research shows *GABAergic mechanism (2018 review).* A review of selank's molecular pharmacology establishes its anxiolytic activity as centered on positive allosteric modulation of GABA receptor binding, with subtype-selective, concentration-dependent effects that diverge from the classical benzodiazepine pattern [8]. *Stress model, combination with diazepam (2017).* In rats subjected to unpredictable chronic mild stress, co-administering diazepam with selank was the single most effective treatment tested for reducing anxiety, restoring behavior toward pre-stress baseline more effectively than either agent alone — evidence consistent with a genuine GABAergic interaction [9]. *Gene expression in frontal cortex (2016).* Selank administration changed expression of genes involved in GABAergic neurotransmission in rat frontal cortex — 45 genes significantly shifted at one hour, 22 genes at three hours — with the direction of those changes correlating positively with the changes produced by GABA itself, direct molecular support for the GABAergic mechanism [10]. *Hippocampal BDNF (2008).* Intranasal selank increased BDNF expression in the rat hippocampus in vivo, tying the peptide to the same neurotrophic-signaling family that semax acts on, albeit through a different upstream route [11]. *Immunomodulation in patients (2008).* In patients with anxiety-asthenic disorders, selank altered the Th1/Th2 cytokine balance and modulated interleukin-6 expression, leading the study authors to describe it as a novel immunomodulator operating alongside its anxiolytic action — one of the few selank findings drawn directly from human patients rather than rodent models [12]. ## Reported effects, cautions & safety The following are **anecdotal, not clinical evidence** — community reports from nootropic forums, peptide-user guides and biohacker blogs, not controlled studies. The most consistently reported effect is a calming without sedation — people describe the volume on anxious thoughts turning down while the mind stays clear, often contrasted with the heaviness of benzodiazepines or the flatness some associate with SSRIs. It is very commonly used situationally, ahead of presentations, exams or difficult conversations, for reduced anticipatory anxiety, with onset frequently noticed within 20 to 40 minutes when taken intranasally. People also describe a steadier, calm-but-sharp focus, a gradual mood lift building over one to two weeks, and more relaxed sociability. A notable minority report little or no effect at all, and among people who do respond, the single-dose effect is widely described as short — a few hours — which leads many to redose through the day. Reported downsides, generally described as mild, include occasional over-calm or drowsiness (often tied to more frequent redosing), nasal irritation from the intranasal solution, and occasional headache. A widely repeated point of praise is the absence of reported tolerance escalation or withdrawal, unlike benzodiazepines — though this rests on short-term anecdotal experience, not long human safety trials. The cited safety cautions below come from the peer-reviewed and regulatory literature: - **Sourcing and purity are unregulated** outside Russia; identity, purity, sterility and actual peptide content vary by supplier and are not independently guaranteed [8]. - **Long-term human safety is not established** beyond a small set of short Russian clinical courses; favorable short-term tolerability reports should be read as preliminary, not as a long-term safety clearance [8][9]. - **Interaction risk is real and largely unstudied.** Because selank is a GABA-receptor modulator, an enkephalinase inhibitor, and a modulator of serotonin and dopamine turnover, combining it with GABAergic sedatives, opioids, or serotonergic/dopaminergic medications has essentially unstudied interaction potential — and the diazepam-combination finding above shows the GABAergic interaction is real, not theoretical [9]. - **Its immune-signaling activity is a distinct, mechanism-based unknown**, given its tuftsin-derived shift in Th1/Th2 cytokine balance [12]. - **It is not a substitute for evaluation of persistent anxiety.** Even the Russian clinical studies were conducted under medical supervision in diagnosed patients, not as unsupervised self-experimentation. - **Pregnancy, nursing and pre-existing conditions are wholly unstudied**, and selank is not FDA- or EMA-approved for any indication. ## Where it fits in Cognitive & Nootropic research Within this desk's neuroplasticity frame, selank occupies a distinct niche from [semax](/semax): both touch BDNF signaling and both inhibit enkephalin-degrading enzymes, but selank's primary studied action is GABAergic anxiolysis rather than the broad neurotrophin-and-vascular neuroprotection semax is studied for. It shares almost nothing mechanistically with [DSIP](/dsip), whose evidence base and proposed action sit on sleep architecture and the HPA axis rather than GABA or neurotrophin signaling. See the [comparison page](/compare) for how the three sit side by side on mechanism and evidence maturity. --- Clarity Peptide Labs keeps a neutral ledger of neuroplasticity and neurotrophic-signaling research — an independent editorial digest, not a clinic, vendor, or source of medical advice.